T1	Participants 692 910	2121/2292 patients (92.5%) had an analysable dataset for either biomarker. 890/2121 patients (42%) presented with an acute coronary syndrome (ACS). 267/890 patients (30%) were within 24 h of an ST-segment elevation MI.
T2	Participants 288 325	The Resolute 'All-Comers' stent trial
